ERA-Net Neuron: PARKCDNF: Development of an experimental therapeutic strategy using the newly identified growth factor CDNF for treatment of Parkinson’s disease, Subprojects 1 and 4

Title of project or programme
ERA-Net Neuron: PARKCDNF: Development of an experimental therapeutic strategy using the newly identified growth factor CDNF for treatment of Parkinson’s disease, Subprojects 1 and 4
Principal Investigators of project/programme grant

Title Forname Surname Institution Country
Prof. Kerstin Kriglstein MRC Laboratory of Molecular Biology UK
 Prof.  Eberhard Fuchs
 Prof.  Mart Saarma University of Helsinki
 Prof.  Raimo Tuominen University of Helsinki
 Prof.  Olle Lindvall Lund University Hospital

Address of institution of lead PI

Institution Albert-Ludwigs-University Freiburg
Street Address Albertstr. 17
City Freiburg
Postcode 79104

Country

  • Germany

Source of funding information
Federal Ministry of Education and Research (BMBF)
Total sum awarded (Euro)
569008
Start date of award
01-02-2009
Total duration of award in months
36
The project/programme is most relevant to

  • Parkinson’s disease

Keywords

Research abstract in English

Lay summary
Parkinson’s disease is a neurodegenerative disease of unknown cause. 12-20 new cases per 100.000 inhabitants per year are reported in developed countries such as Europe. Furthermore, no causal therapy for restoring nigrostriatal neuron loss or slowing down the disease progression is available. Potential and promising therapies may therefore lay in the neurotrophic support of old and environmentally challenged dopaminergic neurons. Mart Saarma and Raimo Tuominen have discovered a new conserved dopamine neurotrophic factor, CDNF, and were able to show that CDNF protects and repairs nigrostriatal neurons in rodent models of PD. CDNF is unique and distinct from other already known neurotrophic factors and is therefore an excellent candidate for a therapeutic lead in PD. The consortium represents a joint effort to promote CDNF as a novel restorative treatment for Parkinson’s disease. At the end of the PARKCDNF project funding, the consortium envisions to be ready to enter the clinic (phase I trials).

ERA-Net Neuron: PARKCDNF: Development of an experimental therapeutic strategy using the newly identified growth factor CDNF for treatment of Parkinson’s disease, Subprojects 1 and 4

Investments > €500k
Germany
Parkinson’s disease & PD-related disorders
2011

 

 

Post
Filter